

Press Release - Euraxi Pharma and AKB-Medservice announce Strategic Partnership

June 6, 2025

[Tours, France] [Bad Birnbach, Germany] – Euraxi Pharma has entered into a strategic partnership with **AKB-medizinische Serviceleistung GmbH (AKB)**, formalizing a collaboration in planning since late 2024.

Together, they establish an integrated model to streamline patient access to innovative therapies—covering both the clinical trial phase (through Decentralized Home Trial Services, HTS) and the post-marketing phase (via Patient Support Programs, PSPs)—with a particular focus on the DACH region (Germany, Austria, Switzerland).

This model is a combination of expertise in the regulatory, coordination and logistics management of HTS projects since 2012 and AKB with their competencies to manage homecare for patients and their families with chronic and/or rare diseases (pediatrics and adult population).

Partnership Objectives :

- **Innovation** : Combine the respective expertise of both companies (CRO and Homecare company)
- **Market Expansion** : Broaden the geographical and demographic reach of the solutions offered over 3 countries
- **Patient access to innovation** : Bridge the gap for patients far from clinical research sites, train the patient to the usage of new drugs or medical devices
- **Multiple benefit for stakeholders** : Participation of patients is more convenient with less travel burden (disabled population, familiar challenges for paediatric patients etc.), schedule of investigations is easier to follow.

«We are thrilled to partner with AKB said Sebastien Louveau (President of Euraxi Pharma). «This partnership will enable us to accelerate our innovation and offer even more efficient solutions to our customers”.

«The alliance with Euraxi Pharma marks a strategic milestone for AKB, enabling us to accelerate access to cutting-edge therapies across the DACH region”, added Peggy Matthes (CEO/Director Clinical Studies). «Together, we are determined to contribute actively to support patient in the DACH region to ease the access to innovative drugs, medical devices whatever the development phase (pre or post marketing authorization)”.

Euraxi is a CRO since 1986 offering either “à la carte” or full services in pre or post marketing authorization projects in drugs or clinical investigation in medical devices (EC or not EC marked). Recognized expertise as early access program and compassionate use program provider and Home Trial Services for more than 10 years with multicountry coverage.

AKB is a specialized German healthcare service provider dedicated to optimizing patient access and support for innovative therapies. With expertise in decentralized clinical trials (Home Trial Services, HTS) and Patient Support Programs (PSPs), AKB bridges gaps between pharmaceutical companies, healthcare providers, and patients across the DACH. The company leverages operational excellence, regulatory expertise, and patient-centric models to streamline therapy delivery—from clinical development through real-world use.

The logo for Euraxi, featuring the word "euraxi" in a bold, dark blue, lowercase sans-serif font. A small blue circle is positioned above the letter 'i'.The logo for AKB, featuring the letters "AKB" in a bold, dark blue, uppercase sans-serif font. Below the letters is a stylized green and blue swoosh that curves upwards. Underneath the swoosh, the text "medizinische Serviceleistungen GmbH" is written in a smaller, dark blue, sans-serif font.